TG Therapeutics, Inc.
TGTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.10 | -3.64 | 0.11 |
| FCF Yield | -0.44% | 0.14% | -0.50% | -0.59% |
| EV / EBITDA | 166.20 | 143.41 | 480.83 | 136.47 |
| Quality | ||||
| ROIC | 3.37% | 5.97% | 1.60% | 5.62% |
| Gross Margin | 82.59% | 86.58% | 87.14% | 85.77% |
| Cash Conversion Ratio | -0.06 | 0.26 | -5.67 | -1.10 |
| Growth | ||||
| Revenue 3-Year CAGR | 40.99% | 166.27% | 255.90% | 390.73% |
| Free Cash Flow Growth | -414.21% | 125.73% | -11.99% | -109.85% |
| Safety | ||||
| Net Debt / EBITDA | 5.49 | 3.31 | 9.90 | 2.27 |
| Interest Coverage | 4.37 | 5.19 | 1.28 | 4.24 |
| Efficiency | ||||
| Inventory Turnover | 0.19 | 0.12 | 0.10 | 0.14 |
| Cash Conversion Cycle | 258.36 | 885.20 | 1,055.18 | 753.05 |